The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
April 14th 2018, 10:18pm
First-line treatment with osimertinib resulted in a clinically meaningful delay in time from randomization to second progression on subsequent treatment or death, establishing the agent as a new standard of care in the frontline setting for patients with EGFR-mutant non–small cell lung cancer.
April 13th 2018, 11:35pm
Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses challenges facing the treatment of patients with stage IV non
April 13th 2018, 11:33pm
Martin Reck, MD, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, discusses the IMpower150 trial data for patients with non
April 13th 2018, 11:31pm
A phase Ib study of necitumumab in combination with abemaciclib failed to meaningfully improve outcomes in patients with stage IV non–small cell lung cancer.
April 13th 2018, 9:31pm
Patients with advanced non–small cell lung cancer and baseline central nervous system metastasis showed control of their CNS metastasis after receiving osimertinib in a real-world clinical setting.
April 13th 2018, 7:46pm
Researchers from Japan recommended against further development of nivolumab for patients with previously treated unresectable or recurrent thymic carcinoma based on their findings from the phase II PRIMER study.
April 13th 2018, 7:31pm
Frontline treatment with osimertinib led to similar improvements in quality of life, including a clinically meaningful improvement in cough, compared with a standard of care EGFR TKIs for patients with advanced EGFR-mutant non–small cell lung cancer.
April 12th 2018, 8:54pm
Maurice Perol, MD, medical oncologist, Centre Leon Berard, discusses the results of the ALEX trial in ALK-positive non–small cell lung cancer.
April 12th 2018, 8:52pm
Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the CheckMate-384 study in non–small cell lung cancer.
April 12th 2018, 8:51pm
Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the quality of life findings from the FLAURA study in non–small cell lung cancer.
April 12th 2018, 8:03pm
In findings consistent with earlier results on efficacy and adverse events reported for the phase III ALEX trial, investigators announced superior patient-reported outcomes for the next-generation tyrosine kinase inhibitor alectinib versus the standard of care TKI inhibitor crizotinib in ALK-positive non–small cell lung cancer.
April 12th 2018, 7:36pm
The frontline regimen of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel has emerged as a potential new standard of care for the treatment of patients with metastatic nonsquamous NSCLC.
April 12th 2018, 6:07pm
Anti PD-L1 immunotherapy with atezolizumab (Tecentriq) was strongly superior to docetaxel in locally advanced or metastatic non–small cell lung cancer, according to 3-year survival findings from the phase II POPLAR study.
March 28th 2018, 5:38am
Currently approved PARP inhibitors have demonstrated similar efficacy in the setting of maintenance therapy for patients with ovarian cancer but differ with respect to the type and frequency of grade 3/4 adverse events, results of a network meta-analysis suggested.
March 27th 2018, 11:36pm
Combination therapy with the PARP inhibitor olaparib and the PD-L1 inhibitor durvalumab induced objective responses in more than 70% of patients with relapsed, platinum-sensitive, BRCA-mutated ovarian cancer.
March 27th 2018, 10:14pm
Brian M. Slomovitz, MD, gynecologic oncologist, Sylvester Comprehensive Cancer Center, University of Miami, discusses GOG 3007, a randomized phase II study of everolimus (Afinitor) and letrozole or hormonal therapy (medroxyprogesterone acetate/tamoxifen) in women with advanced, persistent or recurrent endometrial carcinoma during the 2018 Society of Gynecologic Oncology Annual Meeting.
March 27th 2018, 8:06pm
Jaron Mark, MD, gynecologic oncology fellow, Roswell Park Comprehensive Cancer Center, discusses the implementation of an ultra-restrictive opioid prescription protocol (UROPP) in patients undergoing major gynecologic surgery, which radically decreased dispensed opioids without reducing pain control, during the 2018 Society of Gynecologic Oncology Annual Meeting.
March 27th 2018, 7:27pm
Patients with platinum-resistant/refractory ovarian cancer had durable responses with the combination of the PARP inhibitor niraparib (Zejula) and pembrolizumab (Keytruda).
March 27th 2018, 12:38am
Almost half of patients with platinum-resistant ovarian cancer had objective responses to combination therapy with pembrolizumab plus the antifolate antibody-drug conjugate mirvetuximab soravtansine.
March 26th 2018, 9:11pm
Lavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.